Literature DB >> 6228191

Antibacterial activity of norfloxacin in the gastrointestinal tracts of rats.

P C Frimodt-Møller, K M Jensen, P O Madsen.   

Abstract

The capacities of norfloxacin (MK-0366) and neomycin to reduce the numbers of bacteria in the gastrointestinal tracts of rats were evaluated. Results of a 3-day treatment with norfloxacin were compared with those of a 3-day treatment with neomycin. Both drugs significantly decreased gram-negative and gram-positive bacteria. Norfloxacin effected a significantly greater reduction in numbers of gram-negative bacteria than did neomycin. Norfloxacin also significantly increased the number of anaerobic bacteria. Although neomycin reduced gram-positive bacteria more effectively than did norfloxacin, this difference between the two drugs was not significant. Norfloxacin merits further study for potential as a bowel sterilant.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6228191      PMCID: PMC185373          DOI: 10.1128/AAC.24.4.560

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  9 in total

1.  Apparent absence of transferable resistance to nalidixic acid in pathogenic Gram-negative bacteria.

Authors:  L G Burman
Journal:  J Antimicrob Chemother       Date:  1977-09       Impact factor: 5.790

2.  Historical development of intestinal antisepsis.

Authors:  E J Poth
Journal:  World J Surg       Date:  1982-03       Impact factor: 3.352

3.  Infection prevention in granulocytopenic patients by selective decontamination of the digestive tract.

Authors:  D T Sleijfer; N H Mulder; H G de Vries-Hospers; V Fidler; H O Nieweg; D van der Waaij; H K van Saene
Journal:  Eur J Cancer       Date:  1980-06       Impact factor: 9.162

4.  Clinical experience with prophylactic antibiotic bowel suppression in burn patients.

Authors:  F Jarrett; E Balish; J A Moylan; S Ellerbe
Journal:  Surgery       Date:  1978-05       Impact factor: 3.982

5.  In vitro antibacterial activity of AM-715, a new nalidixic acid analog.

Authors:  A Ito; K Hirai; M Inoue; H Koga; S Suzue; T Irikura; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1980-02       Impact factor: 5.191

6.  In vitro antibacterial activity of norfloxacin (MK-0366, AM-715) and other agents against gastrointestinal tract pathogens.

Authors:  D L Shungu; E Weinberg; H H Gadebusch
Journal:  Antimicrob Agents Chemother       Date:  1983-01       Impact factor: 5.191

7.  In vitro antibacterial activity of norfloxacin (MK-0366).

Authors:  A King; C Warren; K Shannon; I Phillips
Journal:  Antimicrob Agents Chemother       Date:  1982-04       Impact factor: 5.191

8.  Antibacterial activity of norfloxacin.

Authors:  S R Norrby; M Jonsson
Journal:  Antimicrob Agents Chemother       Date:  1983-01       Impact factor: 5.191

9.  Comparative activities of AM-715 and pipemidic and nalidixic acids against experimentally induced systemic and urinary tract infections.

Authors:  K Hirai; A Ito; Y Abe; S Suzue; T Irikura; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1981-01       Impact factor: 5.191

  9 in total
  1 in total

1.  Oral enoxacin for infection prevention in adults with acute nonlymphocytic leukemia. The Enoxacin Prophylaxis Study Group.

Authors:  G H Talbot; P A Cassileth; L Paradiso; R Correa-Coronas; L Bond
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.